{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-040948","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.242308+00:00","generated_at":"2026-06-11T18:39:58.961049+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nkarta Q2 net loss $33.3M ($0.68/share); cash $302.2M; NKX101 shows 67% CR/CRi with Flu/Ara-C","bullets":["Cash and investments $302.2M as of June 30, 2023; cash runway into 2025.","R&D expense $25.1M; G&A $11.7M; non-cash impairment charge $4.1M on right-of-use assets.","NKX101: 4/6 CR/CRi (67%) in AML patients after Flu/Ara-C lymphodepletion; no dose-limiting toxicities.","NKX019 updated data from Phase 1 NHL trial presented at EHA and ICML; expansion cohorts enrolling.","Alyssa Levin appointed CFO and Chief Business Officer effective July 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-040948","json":"https://secwatch.observer/filing/0000950170-23-040948.json","markdown":"https://secwatch.observer/filing/0000950170-23-040948.md","text":"https://secwatch.observer/filing/0000950170-23-040948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023040948/0000950170-23-040948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023040948/nktx-20230810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T18:39:58.961049+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"754743a18f063761a4156a0d37f58fd8b8c452d7","claim":"Nkarta, Inc. reported second quarter ended June 30, 2023 results: net income Net loss was $33.3 million, or $0.68 per basic and diluted share, EPS $0.68 per basic and diluted share.","evidence_excerpt":"Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023040948/0000950170-23-040948-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $33.3 million, or $0.68 per basic and diluted share"},{"label":"EPS","value":"$0.68 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}